Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
07 2021
Historique:
received: 26 02 2021
accepted: 16 06 2021
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 10 8 2021
Statut: epublish

Résumé

Rationally designed protein subunit vaccines are being developed for a variety of viruses including influenza, RSV, SARS-CoV-2, and HIV. These vaccines are based on stabilized versions of the primary targets of neutralizing antibodies on the viral surface, namely, viral fusion glycoproteins. While these immunogens display the epitopes of potent neutralizing antibodies, they also present epitopes recognized by non-neutralizing or weakly neutralizing ("off-target") antibodies. Using our recently developed electron microscopy polyclonal epitope mapping approach, we have uncovered a phenomenon wherein off-target antibodies elicited by HIV trimer subunit vaccines cause the otherwise highly stabilized trimeric proteins to degrade into cognate protomers. Further, we show that these protomers expose an expanded suite of off-target epitopes, normally occluded inside the prefusion conformation of trimer, that subsequently elicit further off-target antibody responses. Our study provides critical insights for further improvement of HIV subunit trimer vaccines for future rounds of the iterative vaccine design process.

Identifiants

pubmed: 34321200
pii: 7/31/eabh2791
doi: 10.1126/sciadv.abh2791
pmc: PMC8318364
pii:
doi:

Substances chimiques

AIDS Vaccines 0
HIV Antibodies 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI100663
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI136621
Pays : United States
Organisme : NIAID NIH HHS
ID : F31 AI131873
Pays : United States
Organisme : NIH HHS
ID : P51 OD011106
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

Références

Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
J Virol. 2000 Jan;74(2):627-43
pubmed: 10623724
Science. 2016 Mar 4;351(6277):1043-8
pubmed: 26941313
Front Immunol. 2018 Jul 17;9:1631
pubmed: 30065725
Elife. 2018 Nov 09;7:
pubmed: 30412051
Curr Opin Immunol. 2020 Aug;65:50-56
pubmed: 32387642
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Cell Rep. 2016 Aug 30;16(9):2327-38
pubmed: 27545891
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11):
pubmed: 28159876
Elife. 2016 Nov 15;5:
pubmed: 27845625
PLoS Pathog. 2018 May 10;14(5):e1006986
pubmed: 29746590
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11947-52
pubmed: 26372963
J Virol. 2013 Sep;87(17):9865-72
pubmed: 23824817
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
Annu Rev Biophys. 2018 May 20;47:499-523
pubmed: 29595997
PLoS Pathog. 2015 Mar 25;11(3):e1004767
pubmed: 25807248
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nature. 2014 Nov 6;515(7525):138-42
pubmed: 25186731
Immunity. 2019 Nov 19;51(5):915-929.e7
pubmed: 31732167
Immunity. 2015 Nov 17;43(5):959-73
pubmed: 26588781
PLoS Pathog. 2020 Aug 11;16(8):e1008665
pubmed: 32780770
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Sci Adv. 2018 Nov 21;4(11):eaau6769
pubmed: 30474059
PLoS Pathog. 2020 Aug 31;16(8):e1008753
pubmed: 32866207
Nat Commun. 2018 Sep 12;9(1):3693
pubmed: 30209313
J Virol. 2015 Oct 28;90(2):813-28
pubmed: 26512083
Nat Med. 2020 Mar;26(3):430-440
pubmed: 32066977
Cell Rep. 2017 Aug 22;20(8):1805-1817
pubmed: 28834745
Cell Rep. 2020 Apr 28;31(4):107583
pubmed: 32348769
J Mol Biol. 2019 May 31;431(12):2223-2247
pubmed: 31028779
Immunol Rev. 2017 Jan;275(1):49-61
pubmed: 28133798
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
Cell Rep. 2018 Aug 21;24(8):1958-1966.e5
pubmed: 30134158
Cell Rep. 2019 May 21;27(8):2426-2441.e6
pubmed: 31116986
Nat Commun. 2015 Sep 25;6:8167
pubmed: 26404402
Immunity. 2018 Aug 21;49(2):288-300.e8
pubmed: 30097292
Cell Rep. 2020 Mar 17;30(11):3755-3765.e7
pubmed: 32187547
Immunol Rev. 2017 Jan;275(1):21-32
pubmed: 28133813

Auteurs

Hannah L Turner (HL)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Raiees Andrabi (R)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.

Christopher A Cottrell (CA)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.

Sara T Richey (ST)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Ge Song (G)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.

Sean Callaghan (S)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.

Fabio Anzanello (F)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.

Tyson J Moyer (TJ)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Wuhbet Abraham (W)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Mariane Melo (M)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Murillo Silva (M)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

Nicole Scaringi (N)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Eva G Rakasz (EG)

Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.

Quentin J Sattentau (QJ)

Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, UK.

Darrell J Irvine (DJ)

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Dennis R Burton (DR)

Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA. burton@scripps.edu andrew@scripps.edu.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Andrew B Ward (AB)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. burton@scripps.edu andrew@scripps.edu.
Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA 92037, USA.
International AIDS Vaccine Initiative-Neutralizing Antibody Center (IAVI-NAC), The Scripps Research Institute, La Jolla, CA 92037, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH